Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
710 Safety and survival results from a phase 1/2 trial of intratumoral agent INT230–6 (cisplatin vinblastine) induces immunological cancer cell death alone or with pembrolizumab in patients with refractory, metastatic cancers
Compose a Response to This Article
Other responses
No responses have been published for this article.